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Yersinia pestis is the bacteria that causes plague, one of the deadliest diseases in 
human history. Three major plague pandemics (The Justinian Plague, the Black Death 
and the Modern Plague) have been recorded. Each caused massive fatalities and has 
become defining events in the time periods in places that were affected. The presence 
of natural plague foci in rodents across the world is one of the risk factors for human 
plague. While plague is a relatively rare problem for most countries, more than 90% 
of plague cases in the world still occur in Africa. This article discusses the threat of 
Yersinia pestis in the modern world by considering its prevalence and severity of 
illness it causes, transmission, antibiotic resistance, and its potential as a bioweapon.  
Keywords: humans, plague, Yersinia pestis, bioterrorism, pandemics, drug 
resistance, microbial, Africa  
 
1. Introduction 
Plague is an infectious disease caused by Yersinia pestis, a gram-negative, nonmotile, 
non-spore-forming coccobacillus. This bacteria appears as bipolar staining with 
Giemsa, Wright’s, or Wayson staining and is also visible by Gram staining. It survives 
within a wide range of temperatures with the optimum being 28⁰C to 30⁰C with pH 
extremes of 5 and 9.6. Y. pestis dies very rapidly if exposed to a UV light, temperatures 
exceeding 40°C or when exposed to intensive desiccation [1].   
Yersinia pestis evolved from the closely related zoonotic enterobacterium Y. 
pseudotuberculosis [2]. Yersinia pestis strain CO92 was amongst the first bacteria to 
be sequenced [3]. Other strains have since been sequenced [4–6,6–8]. The fluid 
nature of its genome and molecular mechanisms contribute to its resilience, virulence 
and ability to persist even after the death of its host [3]. For instance, the bacteria 
evolved to acquire plasmids which enables it to transition into its rodent-flea 
environments and enhance virulence [9]. The bacteria also has specific genes 
involved in host virulence, host colonisation and core cellular function [10]. Yersinia 
pestis uses bacterial strategies to take over host innate immune responses and 
prolong its own survival. Its virulence is determined by specific proteins such as the 
protease Pla and the Yersinia outermembrane proteins (Yops) [11].  
Y. pestis has three different biovars in which each causes a distinct pandemic. The 
three distinct biovars are Antiqua, Mediavalis and Orientalis. Antiqua is found in Africa 
and central Asia whereas Medievalis is limited only to central Asia and Orientalis is 
almost worldwide in its distribution [12]. Recently, researchers reported a new biovar 
called Microtus, found in China [13]. The differences between the biovars can be seen 
on the basis of conversion of nitrate to nitrite and fermentation of glycerol. The first 



































































strain Antiqua has both characteristics. Orientalis converts nitrates to nitrites but does 
not ferment glycerol. Medievalis does not possess either of the characteristics to 
convert nitrates to nitrites or fermenting glycerol [10]. The Microtus strain shows similar 
characteristics with those of Mediavalis and does not utilise arabinose [13].  
1.1 Transmission  
The life cycle of Yersinia pestis involves rodents and its transmission from 
hematophagous adult fleas to animal hosts and between hosts, including humans. 
Infected animals and their fleas can become long-term reservoir hosts for the bacteria. 
Infections can also occur in other animals such as lagomorphs, artiodactyls, 
carnivores, hyracoids, insects, marsupials and primates. Birds also have the tendency 
to spread fleas that carry Y. pestis while predators catch prey that may carry the 
bacteria, which in turn spreads the bacteria around. Thus, Yersinia pestis is 
maintained in nature by animal populations making them accountable for this bacteria 
being endemic in many parts of the world [14]. Plague infection can occur from person 
to person through infectious droplets from the coughs of infected people and contact 
with contaminated bodily fluid or tissue [15]. Besides bites from infected fleas, people 
working with animals such as farming, butchery or animal husbandry are at risk of 
plague infection [16].  
 
1.2 Detection  
 
There are a number of ways in which Yersinia pestis can be detected. Most target the 
fraction 1 (F1) capsular antigen which represents the most immunogenic specific 
protein of the bacteria [17,18]. The most widely used diagnostic tests are the passive 
hemagglutination test and hemagglutination inhibition test. Dipsticks are the most 
frequently used detection methods in the field [19]. Point of care testing of Y. pestis 
during field work or visits to affected areas allows detection in the field without having 
to access a laboratory [20]. Detection by Polymerase Chain Reaction (PCR) may be 
performed by medical staff in the field by using portable real-time quantitative PCR 
thermocyclers [15]. Other detection methods such as biosensors [21,22], 
serodiagnosis [23], lateral-flow immunoassay and up-converting phosphor 
technology-based biosensors [24] have since been introduced and successfully 
evaluated.   
 
In compliance with the European policy (Decision no 082/2013/EU), the EMERGE 
Coordination and the Bundeswehr Institute of Microbiology recommend detecting 
plague by confirming a first positive/negative test result with a second test. As an 
example, a positive PCR amplification confirmed by a culture or immunological test 
conducted in parallel. EMERGE also recommends that additional laboratory 
investigations be considered in the event of obtaining negative results when evaluating 
an early stage of disease when there is suspected plague and progression of clinical 
symptoms [25]. 
 
1.3 Treatment  
 
Treatment for plague should administered as soon as possible [26]. The current 
treatment for plague includes the use of antibiotics, dispense of oxygen, intravenous 


































































plague are streptomycin, tetracycline and chloramphenicol [27]. Other antibiotics that 
can be used to treat plague are as gentamicin, levofloxacin, ciprofloxacin, doxycycline, 
moxifloxacin and chloramphenicol [28].  
 
Alternative methods of treatment in the literature comprise serum therapy, phage 
therapy and bacteriocin therapy. Historically, serum therapy to treat humans with a 
horse serum was conducted by Alexandre Yersin in 1897 [29]. Serum therapy 
however, did induce side effects such as serum sickness and anaphylactic shock. 
Despite this, a significant difference in death rates was found amongst people suffering 
bubonic plague, for which 13% was reported for those treated with serum therapy and 
64% for those untreated. At that time, reduction in death rates was not much different 
between people suffering from septicaemic or pneumonic plague [26,30]. 
 
Phage therapy through bacteriophages was first attempted by d’Herelle in 1925 to 
treat four cases of bubonic plague by using highly virulent anti-plague phage that had 
been isolated in rat faeces. Within several hours after the injection into the buboes the 
patients began to feel better and had 2⁰C average fall in temperature and decreased 
pain in the buboes. All four patients made a recovery. However, when trying to confirm 
the efficacy of the treatment using animal models led to conflicting results. This was 
due to a number of factors such as a poor understanding of the mechanisms of phage–
bacterial interactions, poorly designed and executed experiments and clinical trials 
and the use of undefined phages in the form of non-purified phage preparations [31]. 
Despite this, phage therapy is gaining renewed interest to combat antibiotic resistant 
bacteria [32]. 
 
Bacteriocin therapy through bacteriocins, antimicrobial peptides produced by bacteria 
was used by McGeachie in 1970 to treat bacterial infections. Purified colicins V and K 
were found to show similar inhibitory activities as kanamycin, streptomycin and 
oxytetracycline [33]. Another bacteriocin called Enterocoliticin was tested against 
Yersinia enterocolitica which is a close relative of Y. pestis. The treatment was proven 
to be effective in the early phase of infection [34].  
 
 
1.4 Preventive measures  
 
Plague is classified as a quarantinable disease. The first preventive measure is to stop 
the spread of plague by enhancing surveillance for the disease especially at points of 
entry into countries to ensure that it does not cross borders into other non-infected 
countries. This covers persons, baggage, cargo, containers, conveyances goods [35]. 
The WHO International Health Regulations also recommend that inspection and 
supervision of vector surveillance should be carried out on products that enter the 
country. Monitoring of the rodent populations within a country should be conducted. 
For example, if there is a drastic decrease in rat populations, there is a risk of fleas 
feeding on other animals which may bring upon a human epidemic [36]. 
 
Measures to increase public awareness of plague[37] should be undertaken [35]. 
Contingency planning within all health sector partners in countries at risk of plague 
spread should be carried out [38] In some countries such as Hong Kong, plague is a 


































































the spread of the plague including source finding and contact tracing during which the 
contacts will also be given post-exposure prophylaxis [35]. 
 
Vaccination is a preventive measure for the plague [39–41]. Live attenuated vaccines 
are used in some countries such as Russia [15]. There is also the killed whole cell 
vaccine in use produced by the US army [42]. Due to many reported challenges related 
to vaccination for plague, vaccines are not common in use today. For instance, safety 
concerns have been raised in the use of live attenuated vaccines [43,44]. Research 
on new types of vaccines for the plague is vast. Some of those in development include 
subunit vaccines which use different antigens. Whilst the F1 antigen is not ideal 
because some Yersinia pestis strains do not produce this antigen, the V antigen may 
be selected to compliment the F1 antigen [42]. There is a possibility that genetically 
modified vaccines using a strain called Kimberley 53 that produces ten to hundred-
fold higher antibody titres to F1 and V could attenuated and used as a live-attenuated 
vaccine [45]. Furthermore, DNA vaccines could incorporate the use F1 or V antigen 
DNA [46,47]. This type of vaccine is expected to be useful as part of a prime-boost 
strategy [45]. While different types of plague vaccines have been in development, no 
proven effective vaccine for plague prevention is currently available [15]. There is 
however, a possibility of combining the use of vaccines with antibiotic treatment. 
Recently, researchers have reported a synergistic protective effect in using a live 
vaccine upon exposure to the virus with second-line antibiotic treatment [48]. 
2. Types of plague  
There are three main types of plague and a few rare variants of the disease. The first 
and most common is the bubonic plague. After a bite by an infected flea, Yersinia 
pestis enters the lymphatic system and replicates itself at the nearest lymph node, 
causing it to swell and become inflamed. The bacteria then incubates between one to 
ten days [49]. During the later stages of infection, the bubo can develop open sores 
filled with pus [50]. At this stage, infection may also spread to the lungs and progress 
into more severe clinical symptoms. The symptoms linked with bubonic plague are 
fever, headache, chills, weakness, malaise, myalgia other less common symptoms 
are dizziness, nausea and vomiting [49]. If bubonic plague is left untreated, the fatality 
rate is between 40% to 70% fatality rate. This accounts for 80% to 95% of cases of 
plague worldwide. When treated, the case fatality rate is 5% to 15% [49].    
 
The next type of plague is pneumonic plague where the lungs are infected and can be 
a progression of bubonic plague to this stage or a progression by an infection from an 
individual affected with pneumonic plague. This is the most virulent form of the plague 
and can have the quickest onset with the incubation time sometimes being as short 
as 24 hours or up to 4 days. The symptoms of pneumonic plague are fever, headache, 
weakness, and a rapidly developing pneumonia with shortness of breath, chest pain, 
cough, and sometimes presents with bloody or watery mucous [28]. Pneumonic 
plague is a more severe infection compared to bubonic plague. If pneumonic plague 
is left untreated, it is almost always fatal but most people can survive the infection with 
immediate treatment upon clinical manifestation of the symptoms. Due to the short 
time frame to obtain effective treatment within 24 hours, the case fatality ratio is greater 




































































The third type of plague is septicaemic plague where blood is infected. Primary 
septicaemic plague makes up about 10% to 15% of all cases of plague [51]. 
Septicaemia may also arise as a secondary effect from bubonic plague. It can affect 
people of all ages, but the elderly are more at risk of developing this type of plague 
[52]. It affects the body by causing a self-perpetuating immunological cascade due the 
rapidly replication of Yersinia pestis [28]. This causes a wide array of symptoms such 
as the minor ones like fever, chills, extreme weakness, abdominal pain and shock 
followed by more severe symptoms such as disseminated intravascular coagulopathy, 
multiple organ failure, acute respiratory distress syndrome, haemorrhage in skin and 
serosal surfaces and gangrenous necrosis of acral regions [51]. Septicaemic plague 
is fatal if left untreated. With treatment, the case fatality ratio lies within the range of 
30% to 50% [53]. 
 
Another type of plague is the rare pharyngeal plague [54]. People who eat 
undercooked or raw meat from an animal that has been infected with Y. pestis can get 
infected [55]. Although pharyngeal plague clinical symptoms are similar to those of 
other plagues, those unique to pharyngeal plague are pharyngitis, dysphagia, tender 
submandibular lymphadenitis, tonsillar enlargement and occasional abdominal pain 
[56]. Pharyngeal plague is more likely to occur in Middle East [57,58], North Africa 
[59,60] and Central Asia [61]. Another rare form of plague is gastrointestinal plague 
[53]. The source of infection is raw or undercooked contaminated meat. Other 
infections associated with plague which have been reported are cutaneous plague, 
meningitis, and endophthalmitis [15]. 
 
3. Prevalence and Severity  
 
Natural plague is prevalent in many countries across the world and is endemic in a 
large area of the world [62]. In fact, the effect of plague across the world may be 
underrepresented in data due to unrecognized cases and the failure of countries to 
report plague cases. While plague is still a relatively rare problem for most countries, 
more than 90% of plague cases in the world occur in Africa [12]. The three most 
endemic countries in the world are the Democratic Republic of the Congo, 
Madagascar, and Peru [50]. Madagascar is the most affected country in the modern 
world with reports of plague outbreaks in the population every year [63]. In fact, the 
most recent outbreak at the Uganda-Congo border was reported on the 5th of March 
2019 [64].  
 
A total of 2,417 confirmed cases were reported in the 2017 plague outbreak in 
Madagascar [38,65]. The death toll was 209 leading to a case fatality ratio of 8.6% 
[66]. What stands out about this outbreak is the high amount of pneumonic plague 
cases totalling 1854, of which 76.7% were pneumonic plague. There were 355 
confirmed cases of bubonic plague, comprising 14.7% of cases. There was also a 
single case of septicaemic plague and 207 cases that have not been classified. This 
outbreak differed to outbreaks that occurred in Uganda where 7.1% cases of plague 
were pneumonic [67] and the USA where 8.1% of plague cases were also pneumonic 
[16]. This suggests that human to human transmission was prevalent in the 2017 
Madagascar outbreak. The majority of cases occurred in a very small area of the 
country. Younger patients were more likely to suffer from plague [68]. Between 1996 
and 1998, 60.9% of plague cases in Madagascar occurred in people under the age of 


































































totalled 80% of all cases during this time [66]. In Uganda, a similar pattern in age 
groups was found with the most cases reported in patients under the age of 19 from 
2008 to 2016 [67]. 
 
From 2000 to 2012, there were sixteen reported cases of plague in the USA [65]. In 
view of the vast size of the country, a plausible explanation for the low number of 
plague cases is that the American public may be less likely to come into direct contact 
rodents or other carriers of the plague as the public in Madagascar [16]. Plague cases 
that affected eight veterinarians, five people who worked with animals (e.g. wildlife 
biologist or animal control personnel) and five plague laboratory researchers in the 
USA may be attributed to occupational hazards [16,69,70]. Pets such as dogs may 
also facilitate the transfer of infected fleas into homes through close living proximity 
and interaction with their owners [71]. 
 
4. Bioterrorism potential  
 
Yersinia pestis is regarded as a Category A organism by the CDC. Category A 
organisms are considered to be a high priority agent that poses a risk to national 
security due to its easy transfer from person to person where infection can result in a 
high mortality rate and public panic. Y. pestis infection also requires special action for 
public health preparedness [28]. Currently, under natural conditions the plague is fairly 
well controlled with it still being a rare disease to occur even in most areas of the world 
in which it is endemic. Nevertheless, one of the biggest future dangers may be the 
imminent threat of plague used as a biological weapon [72]. The idea of using plague 
as a biological weapon is not new and has been considered since World War Two.         
  
The history of the research and possible use of Yersinia pestis as a bioweapon began 
with the Japanese military’s research on the use of many different biological weapons. 
The program was led by Shiro Ishii (1932–1942) and Kitano Misaji (1942–1945) and 
the research was performed by a group known as Unit 731 [73]. The first plague 
biological weapon was made by allowing laboratory fleas to feed on infected rats. 
Wheat and rice with infected fleas were scattered over Chinese cities to attempt to 
start a plague epidemic [74]. One case occurred in Ningpo where 100 people died of 
plague after the release of fleas onto the city. Although these attacks were carried out 
to relative success, this did not have much of an effect on the war [75]. 
 
After World War Two, Yersinia pestis continued to be developed in this role, reportedly 
in the Soviet Union and the USA [76,77]. The two countries developed a method for 
introducing Y. pestis by aerosolising the plague directly without having to use fleas as 
carriers [78]. This would make the plague an unpredictable bioweapon and could also 
enable scientists to determine the type of plague to infect victims with.  Whilst the 
release of Y. pestis using fleas caused cases of bubonic plague, the aerosol version 
would cause pneumonic plague which is more virulent and severe [79,80]. In 1970 the 
WHO estimated that in the worst-case scenario that if 50kg of Y. pestis was released 
in a city with a population of 5 million, up to 150,000 people could be infected and 
36,000 of those people would be expected to die.  
 
Today, most countries have stopped conducting offensive bioweapons programmes. 
The United Kingdom ceased in the 1950s, followed by the USA in 1969. The Biological 


































































and completed by the Soviet Union although the latter did not disband their 
bioweapons programme until 1992 [80]. The Yersinia pestis strain that the Soviet 
Union was working on was genetically modified to be multidrug-resistant and 
fluoroquinolone-resistant [51]. In the event that this bioweapon were to be released, 
the drugs that would have been used are streptomycin, gentamicin, tetracycline, or 
fluoroquinolones with doxycycline, ciprofloxacin or chloramphenicol as alternatives to 
treat the pneumonic plague outbreak [81]. This would have also included giving 
antibiotic prophylaxis with doxycycline or ciprofloxacin for seven days to anyone who 
comes into contact with the patients with pneumonic plague [82]. 
 
In the event that a biological threat occurs, affected countries would require strategic 
biosafety management the surveillance, subsequent investigation, treatment and 
control of infection [83,84]. Yersinia pestis is a bioterrorism threat due to a number of 
factors that make it fit for this purpose [85]. The first is the accessibility of Y. pestis due 
to the amount of countries it is endemic in and the possibility for it to be isolated and 
cultured in a laboratory. Furthermore, information for its optimum growth conditions 
are available [86]. Secondly, infection by Y. pestis has a high mortality rate in 
pneumonic plague which can be easily spread between people. Thirdly, access to 
previous research left behind by former scientists who worked on Y. pestis could be 
exploited with the intent of weaponising the strain [87]. Last but not least, antibiotic 
resistance in Y. pestis strains [88,89] could pose to be challenging for affected 




5. Antibiotic resistance 
 
Bacterial resistance to antibiotics is a global challenge [81,91,92]. The problem of 
antibiotic resistance lies in the ability of the bacteria to transfer its antibiotic resistance 
plasmids via conjugation to other non-resistant strains of Y. pestis or to Escherichia 
coli (E. coli) [93]. Antimicrobial susceptibility of isolated strains in Madagascar have 
previously been researched [94]. Recently, two strains of Yersinia pestis were found 
to exhibit antibiotic resistance. Y. pestis 17/95 carries 8 antibiotic resistances on a 
plasmid of 150kb called pIP1202 and is reported to exhibit high-level resistance to 
eight antimicrobial agents used for treatment and some prophylactic drugs. It is also 
resistant to some of the typical alternative drugs such as ampicillin, kanamycin, and 
spectinomycin. While Y. pestis 16/95 has only streptomycin resistance on a plasmid 
of 40 kb called pIP1203, it remains susceptible to other antibiotic treatment [81]. The 
transfer of the antibiotic resistances to E. coli may be important as E. coli has a 
documented history of interbacterial species transmission of antibiotic resistances 
[95]. Currently, both of these strains are confined to Madagascar. If they reach another 
country in which the plague is endemic, antibiotic resistant genes could be spread to 
the endemic plague population. It may also spread to other bacteria in the same way 
that it does with E. coli [96]. Furthermore, if some E. coli carry the plasmid containing 
the resistance genes from Y. pestis, antibiotic resistance may be transferred to other 
bacteria [93].  
 
The rising level of antibiotic resistance in Madagascar may lead to governmental 
pressure to conduct research into alternative methods of treatment instead of sole 


































































bacteriophage[97] which is expected to eventually become one of the most effective 
antibacterial alternatives [98,99]. The bacteriophage method is offers more specific 
than serum therapy and bacteriocin treatment as the bacteriophages only destroy the 
targeted pathogenic bacteria [100]. Another advantage of the bacteriophage is that 
phage mutation is significantly higher than that of bacteria mutation so it responds 
quickly to phage‐resistant bacterial mutants. Bacteriophages are also cheaper to 
develop than new antibiotic development. In addition, few side-effects from 
bacteriophage treatment have been reported [100]. Nevertheless, the development of 
bacteriophage treatment may face some challenges such as toxin encoding amongst 
phages, a lack of pharmacokinetic data and neutralisation of the phase by the host 
immune system leading to the failure of the treatment [100]. 
  
6. Trade routes and human travel  
 
The routes that support the spread of Y. pestis strains from Madagascar to other parts 
of the world are similar to those of historical trade routes. Today, these trade routes 
via air and sea are as vast as ever. Wildlife trade can potentially bring zoonotic 
diseases to different countries [101].   Madagascar has a large amount of exports that 
go around the world. The main export is vanilla which goes to many different countries 
with top importers such as France, the USA, Germany, China and Japan [102]. 
Therefore, it is possible for Y. pestis to be moved across these trade routes to other 
countries. The spread of Y. pestis can happen through human travel via tourism if 
people travel to Madagascar during the seasons of the year when plague is most 
prevalent. Tourists may get infected and return to their own country before symptoms 
appear. During the 2017 outbreak in Madagascar, nine countries and overseas 
territories were listed as priority countries for plague preparedness due to the trade 
and travel links of the countries to Madagascar. These countries and overseas 
territories were Comoros, Ethiopia, Kenya, Mauritius, Mozambique, La Réunion 
(France), Seychelles, South Africa, and Tanzania [38]. 
 
7. Economic consequences 
 
The effect of plague is detrimental in countries during and after outbreaks. The 
consequences of affected locations are deteriorating local businesses and loss of 
income to the public places that had to be shut down. For instance, the outbreak in 
Western India in 1994 affected food vendors, restaurants, and public gatherings [103]. 
This plague was a relatively small with 700 cases of plague. However, due to the fear 
of plague infection, many restrictions were placed upon air and sea travel and trade of 
India following recommendations from health authorities. This caused the collapse of 
trade and the tourism industry which caused an estimated 1.8 billion dollars damage 
to the economy. The consequence of this was a definite impact on public life and the 
economy of India at that time [103,104]. 
 
8. Concluding remarks  
 
This article discussed the threat of Yersinia pestis in the modern world. The plague 
has the potential to cause many fatalities across a global scale if it is not controlled or 
used as a weapon. The classification of plague as a re-emerging disease with the high 
number of cases across Madagascar suggests that Y. pestis can cause serious 


































































for it [1]. The threat of antibiotic resistance in the emergence of the two resistant 
natural stains of Y. pestis may become a real problem in the future if other antibiotics 
or alternative treatments are not discovered [81]. The threat of bioterrorism and 
bioweapons by way of Y. pestis has the potential to cause thousands of deaths in a 
heavily populated area [80,87]. Exercises in bioterrorism awareness and 
preparedness should be made available to the general public [105]. Further research 
is needed to find alternatives to antibiotic treatment to combat the risk of plague. Cost-
effective and sustainable preventive and management strategies should be deployed 
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